多时相-磁控触释载药系统用于青光眼术后精准瘢痕调控及机制研究

青光眼是世界首位不可逆致盲眼病，严重损害视功能。滤过术是最主要治疗手段，常因术区过度瘢痕化致手术失败而致盲。现有抗瘢痕药物毒性大或有效性不足，申请人及团队2005年来一直致力青光眼术区瘢痕调控，国际上首次将Pirfenidone(PFD)用于眼科术后抗瘢痕，阐明其抗瘢痕的优势和半衰期短的不足，并通过胶体溶液、植入型凝胶、载药接触镜等缓释系统提高其生物利用度。鉴于青光眼术后不同时期瘢痕调控侧重点不同，需要分时相干预，本研究拟在前期基础上，建立国际领先的磁场介导药物控释技术，结合团队已有的眼部多腔精确载药、药物递送技术，研发多时相-磁控触释载药系统，实现抗瘢痕药物PFD在眼部的分时相控制性释放，进行青光眼术后精准瘢痕调控并验证其机制，提高手术成功率，减少青光眼盲。

Glaucoma is the leading cause of irreversible blindness in the world which brings critical visual function damage. Glaucoma filtering surgery (GFS) has been demonstrated the greatest and most sustainable hypotensive effect when intraocular pressure cannot be controlled, but postoperative scarring in the filtering pathway often leads to surgical failure. Existing anti-scarring drugs are highly toxic or insufficiently effective，so our previous research has been focused on regulating the wound healing of postoperative region since 2005 and internationally reported Pirfenidone (PFD) could be used in proliferative lesion of postoperative region in ophthalmology for the first time. And our pilot studies have demonstrated the strengths and weaknesses of PFD as an anti-scar formation medication. Besides, We used the colloidal solution, implant hydrogel, contact lens system for drug delivery to improve the fraction of bioavailability. In view of the different focus of scar control in different postoperative stages of glaucoma, the scar formation regulating needs multi-temporal intervention. So we can precisely regulate the wound healing after glaucoma filtration surgery. Through partition of drug load, different medication proportion and high throughput chip of postoperative tissue, we aim to further clarify the regulating mechanism of wound healing after GFS and contribute to blindness prevention.